Mum

European Commission Approves KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma

Retrieved on: 
月曜日, 4月 4, 2022
Population, Dacarbazine, The New England Journal of Medicine, Clinical trial, CHMP, Autoimmunity, Caregiver, Adult, European Commission, CRS, European Directive on Traditional Herbal Medicinal Products, Survival, Committee for Medicinal Products for Human Use, Cancer, TCR, EC, OS, Fever, Royal commission, Ipilimumab, Hope, Committee, Itch, Curie Institute, Nasdaq, Rash, Patient, Pembrolizumab, Infection, Pharmaceutical industry, Mum, Immunocore

KIMMTRAK, a bispecific T-cell engager, is the first therapy to demonstrate a survival benefit in patients with unresectable or metastatic uveal melanoma.

Key Points: 
  • KIMMTRAK, a bispecific T-cell engager, is the first therapy to demonstrate a survival benefit in patients with unresectable or metastatic uveal melanoma.
  • Data from the trial, the largest Phase 3 trial undertaken in mUM, showed that KIMMTRAK demonstrated unprecedented median OS benefit as a first-line treatment.
  • KIMMTRAK represents a paradigm shift in the treatment of unresectable or metastatic uveal melanoma.
  • Unresectable or metastatic uveal melanoma typically has a poor prognosis and had no approved treatment until KIMMTRAK.

Delcath Systems to Participate in the Lytham Partners Spring 2022 Investor Conference

Retrieved on: 
火曜日, 3月 29, 2022
Mum, Delcath Systems, Liver, Melphalan, FDA, Sale, Mother, PHP, Vaccine

Management will be participating in virtual one-on-one meetings throughout the event.

Key Points: 
  • Management will be participating in virtual one-on-one meetings throughout the event.
  • To arrange a meeting with management, please contact Lytham Partners at [email protected] or register at www.lythampartners.com/spring2022invreg .
  • Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.
  • The companys proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Delcath Systems to Host Fourth Quarter and Full Year 2021 Results

Retrieved on: 
火曜日, 3月 15, 2022
GLOBE, PHP, FDA, Nasdaq, Delcath Systems, Mother, Internet, Sale, Melphalan, Mum, Liver

NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced todayit will host a conference call on March 25, 2022, at 8:30 AM Eastern Time to discuss results for its fourth quarter and full year ended December 31, 2021.

Key Points: 
  • NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced todayit will host a conference call on March 25, 2022, at 8:30 AM Eastern Time to discuss results for its fourth quarter and full year ended December 31, 2021.
  • To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.
  • The call will also be available over the Internet and accessible at:
    Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.
  • The companys proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Delcath Systems to Present at the 34th Annual Roth Conference

Retrieved on: 
木曜日, 3月 10, 2022
Nasdaq, Mum, Delcath Systems, FDA, Conference, GLOBE, Sale, Mother, Melphalan, PHP, Liver

NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will present at the 34th annual Roth Conference on Monday, March 14, 2022, at 3:30 PM PT.

Key Points: 
  • NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will present at the 34th annual Roth Conference on Monday, March 14, 2022, at 3:30 PM PT.
  • A webcast of the presentation will be available at: https://wsw.com/webcast/roth43/dcth2/1882196
    To learn more or to schedule a one-on-one meeting with management, please contact your conference representative or [email protected].
  • Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.
  • The companys proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Foghorn Therapeutics Provides Full Year 2021 Corporate Update and 2022 Outlook

Retrieved on: 
木曜日, 3月 10, 2022
Nasdaq, Mum, Clinical trial, Â, Choroid, Cost sharing, Chromatin, Ciliary body, BAF, Company, Ligament, Research, U.S. Securities and Exchange Commission, Gottschalk, BRD9, Iris, Cell, Sarcoma, AML, Cancer, 23rd Street station (IND Eighth Avenue Line), Mutation, Economics, Synovial sarcoma, MDS, Adult, Bone marrow, Acute leukemia, ARID1A, GLOBE, BRM, Gene expression, Acute myeloid leukemia, Security (finance), ATPase, Blood, Myelodysplastic syndrome, BRG1, Therapy, Lilly, Neoplasm, Program, ARID1B, Forward-looking statement, NSCLC, Protein, Fine chemical, Cryptocurrency, Pharmaceutical industry, Vaccine, Dietary supplement, Foghorn

CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today provided a corporate update including the Company’s 2021 key achievements and 2022 strategic priorities in conjunction with its 10-K filing for the year ended December 31, 2021. With an initial focus in oncology, Foghorn’s Gene Traffic Control® Platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.

Key Points: 
  • In January 2022, Foghorn added Dannette Daniels as our Vice President, Protein Degrader Platform, continuing our investment in and expansion of our protein degrader capabilities.
  • In December 2021, Foghorn and Lilly announced a strategic collaboration for novel oncology targets using Foghorns proprietary Gene Traffic Control Platform.
  • In December 2021, Foghorn and Loxo Oncology at Lilly entered into a strategic collaboration for novel oncology targets.
  • Foghorn Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system.

Immunocore to present at Oppenheimer’s 32nd Annual Healthcare Conference

Retrieved on: 
水曜日, 3月 9, 2022
Nasdaq, Safety, Private Securities Litigation Reform Act, Company, Marketing, Infection, U.S. Securities and Exchange Commission, Survival, Annual report, Cancer, Conference, Autoimmunity, Omicron, Risk, Patient, Security (finance), TCR, Autoimmune disease, COVID-19, Adult, Pharmaceutical industry, Mum, Immunocore

& ROCKVILLE, Md., US, 9 March 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease, today announced that management will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference.

Key Points: 
  • & ROCKVILLE, Md., US, 9 March 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease, today announced that management will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference.
  • The presentation is scheduled for Wednesday, March 16, 2022 at 9:20 a.m. Eastern Time (ET).
  • The presentation will be webcast live during the conference and will be available in the Investors section of Immunocores website at www.immunocore.com .
  • A replay of the presentation will be made available for a limited time.

Delcath Systems Achieves Medical Device Regulation Certification for CHEMOSAT® in Europe

Retrieved on: 
水曜日, 3月 2, 2022
Medical device, Mum, Documentation, IIB, Safety, Certification, FDA, Medical device regulation, Sale, Delcath Systems, Mother, EC, MDD, PHP, Liver, MDR, Nasdaq, Melphalan, GLOBE, UDI, EU

NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce that on February 28 its CHEMOSAT Hepatic Delivery System received Medical Device Regulation (MDR) certification under the new European Medical Devices Regulation [2017/745/EU].

Key Points: 
  • NEW YORK, March 02, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce that on February 28 its CHEMOSAT Hepatic Delivery System received Medical Device Regulation (MDR) certification under the new European Medical Devices Regulation [2017/745/EU].
  • Since April 2012, Chemosat had been certified under a previous regulation, the Medical Device Directive [2007/47/EC] (MDD), which is being replaced by MDR.
  • Under MDR, CHEMOSATs designation has changed from a Class IIb to a Class lll medical device.
  • Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers.

Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma

Retrieved on: 
金曜日, 2月 25, 2022
The New England Journal of Medicine, European Organisation for Research and Treatment of Cancer, Rash, Uveal melanoma, Population, HIV disease progression rates, European Medicines Agency, Public health, Fever, Research, OS, Clinical trial, Itch, Disease, Treatment, Adult, European Directive on Traditional Herbal Medicinal Products, Ipilimumab, Infection, FDA, Nasdaq, Committee for Medicinal Products for Human Use, EMA, TCR, Patient, Marketing, Union, CRS, Committee, CHMP, Autoimmunity, Dacarbazine, Pembrolizumab, Pharmaceutical industry, Immunocore, EU, Cancer, Mum

The CHMPs recommendation of KIMMTRAK brings us closer to providing a much-needed treatment option to patients in Europe, said Bahija Jallal, Chief Executive Officer of Immunocore.

Key Points: 
  • The CHMPs recommendation of KIMMTRAK brings us closer to providing a much-needed treatment option to patients in Europe, said Bahija Jallal, Chief Executive Officer of Immunocore.
  • This year, hundreds of people across the EU will be diagnosed with metastatic uveal melanoma.
  • Data from the trial, the largest Phase 3 trial undertaken in mUM, showed that KIMMTRAK demonstrated unprecedented median OS benefit as a first-line treatment.
  • Unresectable or metastatic uveal melanoma typically has a poor prognosis and had no approved treatment until KIMMTRAK.

Provectus Biopharmaceuticals Announces Acceptance of PV-10® Metastatic Uveal Melanoma Abstract for Oral Presentation at 2022 International Society of Ocular Oncology (ISOO) Congress

Retrieved on: 
水曜日, 2月 16, 2022
Ophthalmology, Patient, Family, Legislation, Company, Hematology, ISOO, OTCQB, Forward-looking statement, National, Immunotherapy, Congress, Dermatology, International Society, Clinical trial, Adult, Safety, Immunogenic cell death, Virology, Liver, Melanoma, Mum, CT, Microbiology, NIH, Drug discovery, GLOBE, Uveal melanoma, Pharmaceutical industry, Medical imaging

This PV-10-induced functional T cell response may be enhanced and boosted in combination with immune checkpoint blockade (CB).

Key Points: 
  • This PV-10-induced functional T cell response may be enhanced and boosted in combination with immune checkpoint blockade (CB).
  • IL PV-10 has been administered to over 450 patients with melanoma and cancers of the liver in both monotherapy and combination therapy settings.
  • Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company developing immunotherapy medicines for different disease areas based on a family of small molecules called halogenated xanthenes.
  • Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements.

Immunocore to present at the SVB Leerink Global Healthcare Conference

Retrieved on: 
金曜日, 2月 11, 2022
Patient, Autoimmune disease, Cancer, Infection, Company, U.S. Securities and Exchange Commission, Security (finance), Private Securities Litigation Reform Act, Nasdaq, Adult, Autoimmunity, Safety, Annual report, Omicron, Q&A, Survival, Risk, Marketing, Conference, COVID-19, TCR, Pharmaceutical industry, Immunocore, Mum

& ROCKVILLE, Md., US, 11 February 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease, today announced that management will participate in the virtual 11th Annual SVB Leerink Global Healthcare Conference.

Key Points: 
  • & ROCKVILLE, Md., US, 11 February 2022) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease, today announced that management will participate in the virtual 11th Annual SVB Leerink Global Healthcare Conference.
  • The presentation is scheduled for Friday, February 18, 2022 at 12:00 p.m. Eastern Time (ET).
  • The presentation and Q&A session will be webcast live during the conference and will be available in the Investors section of Immunocores website at www.immunocore.com .
  • A replay of the presentation and Q&A will be made available for a limited time.